Ficerafusp alfa enters phase 2/3 trial for recurrent/metastatic head and neck cancer, evaluating its combination with ...

Clear cell sarcoma is deemed highly aggressive due to its early tendency to metastasize, genetic mutations, and difficulty in ...

Groundbreaking findings from the landmark CLEAR (Clinical trial Comparing Lenvatinib with Ecerolimus or Pembrolizumab in ...

The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza) for adult patients with a rare condition ...

Shannin Desroches fought for a diagnosis after being dismissed. Now she tells PEOPLE that she's been given a 5% chance of ...

Researchers have found that a cancer outside the brain makes electrical connections with the nervous system to fuel cancer growth and aid its spread.

The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...

The U.S. Food and Drug Administration (FDA) has approved vimseltinib (RomvimzaTM) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT). TGCT is a tumor of the tissue ...

Cancer cells work together to source nutrients from their environment -- a cooperative process that was previously overlooked by scientists but may be a promising target for treating cancer.